drugset
drugset / Trial / NCT05518708

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

NCT05518708 ↗

Phase 1 Completed 94 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3032950 in healthy male subjects following intravenous (Part A) or subcutaneous (Part B) administration of single rising doses.

Timeline

Start
2022-09-27
Primary completion
2023-09-21
Completion
2023-09-21

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3032950 Unknown — Intravenous

Indications

No indication recorded.